Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474973 | 0.78 | GAA (0.39) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL6319563 | 0.76 | GAA (0.38) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL7590859 | 0.76 | GAA (0.38) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL6313690 | 0.76 | GAA (0.38) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL8420585 | 0.76 | GAA (0.34) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL6314494 | 0.74 | GAA (0.52) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL10570791 | 0.73 | GAA (0.35) | GAAALDH1A1LMNAHSD17B10 | |
| Acetic Acid SCHEMBL9958361 | 0.71 | GAA (0.34) | GAAALDH1A1LMNAHSD17B10 | |
| SCHEMBL1455930 | 0.70 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL204648 | 0.70 | GAA (0.41) | GAAALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1059927-B1 | CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | PHARMASSET, INC. | 2005-11-10 | — | — | US | disclosed |
| US-6927291-B2 | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides | PHARMASSET, LTD. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1363927-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | Pharmasset Limited (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | GILEAD PHARMASSET LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002070533-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | PHARMASSET LTD. (BB) | 2002-09-12 | — | — | WO | disclosed |
| US-6369273-B1 | ARYL ALCOHOLS OR ESTERS FOR ELEVATION OF PYRUVATE DHYDROGENASE | ASTRAZENECA AB (SE) | 2002-04-09 | — | — | US | disclosed |
| EP-1059927-A1 | CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044618-A1 | CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DUS2, DERA | GAA 627/4885ALDH1A1 853/4885LMNA 696/4885 |
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DERA, DUS2 | GAA 491/4885ALDH1A1 837/4885LMNA 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.